Peptides & Amino Acids

Signal inhibition of TGFβ1 is often used for stem cell reprogramming and iPSC differentiation. Small kinase inhibitors are commonly used, but they lack specificity and may perturb other signaling pathways, causing cytotoxicity.PG-002, a chemically-synthesized cyclic peptide with specific binding ability against TGFβ1 and lacks membrane-permeability, can specifically inhibit TGFβ1 signaling at extracellular conditions, making it a suitable replacement for small kinase inhibitors. The molecular weight of PG-002 is 2587.90 (acetate).

Brain-derived neurotrophic factor (BDNF) is a growth factor derived from the brain that binds to TrkB receptors, regulating neuronal growth, survival, and synaptic function. PG-003, an alternative peptide to BDNF, is a chemically-synthesized homodimeric cyclic peptide with specific binding ability against the TrkB receptor. Upon binding, PG-003 induces dimerization of the TrkB receptor, triggering subsequent signaling events in cells as a TrkB agonist. It should be noted that PG-003 is believed to have no binding or agonistic activity towards the p75 receptor, which is a low-affinity nerve growth factor receptor that binds to BDNF.The molecular weight of PG-003 is 5151.66 (acetate), and 10 µg of PG-003 exhibits equivalent activity to 25 µg of human BDNF.

Noggin is a BMP antagonist that supports the development of organoids derived from epithelial tissues, iPSCs, and ESC differentiation. It is commonly used for developing organoids of the intestine, pancreas, lung, and tumor-derived tissues, as well as for stem cell differentiation into neural and microglial lineages. PG-004, a Noggin-like peptide, is a chemically-synthesized cyclic peptide that inhibits the BMP4 and BMP7 families in the same manner as Noggin, at a comparable level on a molar basis. The molecular weight of PG-004 is 2920.15 (acetate), and 12.5 µg of PG-004 is equivalent to 100 µg of human Noggin.

PG-005, a selective inhibitor of BMP7, is a novel functional cyclic peptide capable of selectively inhibiting the signaling of the BMP7 family (BMP5, BMP6, BMP7). Together with PG-006, a BMP4 selective inhibitor, PG-005 and PG-006 enable the selective inhibition of BMP4 and BMP7 signaling, which was not possible with existing small kinase inhibitors or Noggin. This peptide can be utilized for detailed analysis and control of BMP signaling, as well as for the construction of new cellular differentiation pathways. The molecular weight of PG-005 is 2085.29 (acetate), and it exhibits comparable inhibitory activity against the BMP7 family to Noggin on a molar basis.

PG-006, a selective inhibitor of BMP4, is a novel functional cyclic peptide capable of selectively inhibiting the signaling of the BMP4 family (BMP2, BMP4). Together with PG-005, a BMP7 selective inhibitor, PG-006 and PG-005 enable the selective inhibition of BMP4 and BMP7 signaling, which was not possible with existing small kinase inhibitors or Noggin. This peptide can be utilized for detailed analysis and control of BMP signaling, as well as for the construction of new cellular differentiation pathways. The molecular weight of PG-006 is 3301.59 (acetate), and it exhibits comparable inhibitory activity against the BMP4 family to Noggin on a molar basis.

NY-ESO-1 (157-165) peptide – SLLMWITQC HLA-A*02 Major Histocompatibility Complex (MHC) allele HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA), that are cell surface receptors, presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood, cell death will be initiated via apoptosis. NY-ESO-1 protein Peptides presented by MHC class I molecule, are usually between 7 and 11 amino acids, originating from proteins expressed by the cell. SLLMWITQC peptide derives from New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt – P78358) protein, which is part of a well-characterized group of cancer/testis antigens (CTAs). Normally, NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas, as well as in many other solid tumors and hematological malignancies. NY-ESO-1 (157-165) peptide application Class I

NY-ESO-1 (157-165) peptide – SLLMWITQC HLA-A*02 Major Histocompatibility Complex (MHC) allele HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA), that are cell surface receptors, presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood, cell death will be initiated via apoptosis. NY-ESO-1 protein Peptides presented by MHC class I molecule, are usually between 7 and 11 amino acids, originating from proteins expressed by the cell. SLLMWITQC peptide derives from New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt – P78358) protein, which is part of a well-characterized group of cancer/testis antigens (CTAs). Normally, NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas, as well as in many other solid tumors and hematological malignancies. NY-ESO-1 (157-165) peptide application Class I

NY-ESO-1 (157-165) peptide – SLLMWITQC HLA-A*02 Major Histocompatibility Complex (MHC) allele HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA), that are cell surface receptors, presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood, cell death will be initiated via apoptosis. NY-ESO-1 protein Peptides presented by MHC class I molecule, are usually between 7 and 11 amino acids, originating from proteins expressed by the cell. SLLMWITQC peptide derives from New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt – P78358) protein, which is part of a well-characterized group of cancer/testis antigens (CTAs). Normally, NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas, as well as in many other solid tumors and hematological malignancies. NY-ESO-1 (157-165) peptide application Class I

NY-ESO-1 (157-165) peptide – SLLMWITQC HLA-A*02 Major Histocompatibility Complex (MHC) allele HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA), that are cell surface receptors, presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood, cell death will be initiated via apoptosis. NY-ESO-1 protein Peptides presented by MHC class I molecule, are usually between 7 and 11 amino acids, originating from proteins expressed by the cell. SLLMWITQC peptide derives from New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt – P78358) protein, which is part of a well-characterized group of cancer/testis antigens (CTAs). Normally, NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas, as well as in many other solid tumors and hematological malignancies. NY-ESO-1 (157-165) peptide application Class I